← FDA DRUG APPROVALS

FDA ANDA · ANDA204730

FROVATRIPTAN SUCCINATE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA204730
TYPE
ANDA
ORIGINAL APPROVAL
2016-03-11
LATEST ACTION
2019-10-24
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

FROVATRIPTAN SUCCINATEPrescription
FROVATRIPTAN SUCCINATE EQ 2.5MG BASE · TABLET · ORAL

Approval history

2019-10-24Labeling · Supplement 2 · standardAP
2016-03-11UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →